Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10917760 | Radiotherapy and Oncology | 2016 | 7 Pages |
Abstract
Patients with elevated pre-SABR non-target lung FDG-PET uptake are at increased risk of symptomatic RP after lung SABR. Our predictive model suggests patients with mean non-target lung SUVÂ >Â 0.56 and MLDÂ >Â 5.88Â Gy EQD2 are at highest risk. Our predictive model should be validated in an external cohort before clinical implementation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Aadel A. Chaudhuri, Michael S. Binkley, Joseph Rigdon, Justin N. Carter, Sonya Aggarwal, Sara A. Dudley, Yushen Qian, Kiran A. Kumar, Wendy Y. Hara, Michael Gensheimer, Viswam S. Nair, Peter G. Maxim, David B. Shultz, Karl Bush, Nicholas Trakul,